key: cord-0303276-hefb2tmv authors: Shastri, J.; Agrawal, S.; Chatterjee, N.; Gupta, H. title: A prospective, single-center study to evaluate the clinical performance of Meril ABFind in individuals vaccinated against COVID-19 date: 2022-01-16 journal: nan DOI: 10.1101/2022.01.15.22269231 sha: 3d866fc6b03e0a1dd5ededd0b2d3d225f2b22ea0 doc_id: 303276 cord_uid: hefb2tmv Background: Accurate rapid antibody detection kits requiring minimum infrastructure are beneficial in detecting post-vaccination antibodies in large populations. ChAdOx1-nCOV (COVISHIELD) and BBV-152 (Covaxin) vaccines are primarily used in India. Methods: In this single-centre prospective study, performance of Meril ABFind was investigated by comparing with Abbott SARS-CoV-2 IgG II Quant (Abbott Quant), GenScript cPass SARS-CoV-2 neutralization antibody detection kit (GenScript cPass), and COVID Kawach MERILISA (MERILISA) in 62 vaccinated health care workers (HCW) and 40 pre-pandemic samples. Results: In the vaccinated subjects, Meril ABFind kit displayed high sensitivity of 93.3% (CI, 89.83%-96.77%), 94.92% (CI, 91.88%-97.96%), and 90.3% (CI, 86.20%-94.4%) in comparison to Abbott Quant, MERILISA, and GenScript cPass respectively. The results of the Meril ABFind in the COVISHIELD-vaccinated group were excellent with 100% sensitivity in comparison to the other three kits. In the Covaxin-vaccinated group, Meril ABFind displayed sensitivity ranging from 80% to 88.9%. In control samples, there were no false positives detected by Meril ABFind, while Abbott Quant, MERILISA, and GenScript cPass reported 2.5%, 10.0%, and 12.5% false positives, respectively. In the pre-pandemic controls, specificity of Meril ABFind was 100%, Abbott Quant 97.5%, MERILISA 90%, and GenScript cPass 87.5%. Conclusion: The Meril ABFind kit demonstrated satisfactory performance when compared with the three commercially available kits and was the only kit without false positives in the pre-pandemic samples. This makes it a viable option for rapid diagnosis of post vaccination antibodies. Introduction 34 SARS-CoV-2 which belongs to Betacoronavirus genus and Coronaviridae family is the causative 35 agent for COVID-19. The spike protein (S-glycoprotein) present on the surface of the virus has a 36 receptor binding domain (RBD) which binds to the angiotensin-converting enzyme 2 (ACE2) present 37 on the cell surfaces and mediates the entry of this virus inside the host cell (1) . Within the first three 38 weeks of getting infected with the virus, the patients develop antibodies against the RBD of the viral 39 spike protein (2). Early development of antibodies is important for survival and control of infection 40 in the patients. These neutralizing antibodies provide protection from future infection by interfering 41 with the interaction between the virus's spike RBD and host's ACE2. 42 India has primarily used ChAdOx1-nCOV (COVISHIELD™) and BBV-152 (Covaxin™) vaccines 43 with health care workers (HCW) being the first group to get vaccinated. Serological tests can detect 44 the humoral immune response following past infection and vaccination, and they can be useful for 45 serological studies. Serology has also been used to make clinical decision on therapeutic 46 interventions (3). While accurate laboratory based serological assays are available in India, a large 47 rural population mandates reliable serological assays to detect humoral immunity following 48 vaccination and post infection which can be performed without expensive laboratory equipment and 49 cumbersome techniques. To address this unmet need, several companies are working on the 50 development of reliable antibody testing kits with adequate sensitivity and specificity (4). Different 51 diagnostic kits are available to identify individuals with immune response after the vaccine 52 administration. Testing a huge number of vaccinated individuals with a diagnostic assay which 53 requires complicated instruments and infrastructure would be cumbersome and would not be 54 economical. In the given situation, a rapid test would be advantageous owing to speed of 55 performance, quick results and minor requirements of equipments and infrastructure. 56 The Meril ABFind kit (Meril Diagnostics Pvt. Ltd., India) can detect circulating SARS-CoV-2 57 neutralizing antibodies that block the interaction between the RBD of the viral spike glycoprotein and 58 the ACE2 cell surface receptor in serum, plasma and whole blood. This study was designed to 59 investigate the clinical performance of this rapid antibody testing kit by evaluating its diagnostic 60 sensitivity and specificity for the qualitative detection of neutralizing antibodies in defined and 61 characterized specimens. For evaluating the performance of this kit, the results obtained were 62 compared with the results obtained using three other commercially available kits viz. Abbott The baseline demographics and the medical history of the participants were collected for analysis and 80 evaluation. 81 One 5 ml vial of blood was collected by venipuncture from the cubital vein in serum separator tubes. 83 Separated plasma was used for testing in all four tests. 40 stored pre-pandemic samples were used as 84 a known negative control. These samples were collected in 2018 from patients with an acute febrile 85 illness. Plasma was separated and stored at -80 °C in our laboratory (Molecular Laboratory, Kasturba 86 Hospital for Infectious Diseases, Mumbai, India). 87 All the samples were tested first using Abbott SARS-CoV-2 IgG II Quant (Abbott Quant) . Then the 89 samples were tested using the Meril ABFind kit and the two commercially available kits, COVID 90 Kawach MERILISA (MERILISA) and GenScript cPass SARS-CoV-2 neutralization antibody 91 detection kit (GenScript cPass). 92 The Abbott Quant kit results were beneficial in comparing anti-RBG IgG in the COVISHIELD-and 93 Covaxin-vaccinated subjects in a quantitative manner. Meril ABFind kit is a qualitative membrane-94 based immunoassay for the detection of SARS-CoV-2 neutralizing antibody in whole blood, serum 95 or plasma. This detection kit utilizes a colloidal gold labeled SARS-CoV-2 recombinant Receptor 96 Binding Domain (rRBD) which binds with the SARS-CoV-2 neutralizing antibody of IgG class if 97 present in the sample to give a colored band. A control band must be present for the test to be 98 considered valid. A control band and a test band was considered positive, a control band without a 99 test band was considered negative and absence of the control band was considered invalid 100 irrespective of the test band. The test specimen was diluted in 1:10 ratio with sample dilution buffer 101 and was added on the membrane strip, the results were read at the end of 20 minutes. 102 The Abbott SARS-CoV-2 IgG II Quant assay is a two-step automated chemi-luminescent 103 microparticle immunoassay (CMIA) intended for the qualitative and quantitative determination of 104 IgG antibodies to the RBD of the spike protein of SARS-CoV-2 in human serum and plasma. The 105 analytical measurement interval was stated as 21 to 40,000 AU/ml, and positivity cut off was 106 ≥50 AU/ml (defined by manufacturer) (5). 107 GenScript cPass SARS-CoV-2 neutralization antibody detection kit is a blocking ELISA detection 108 tool which mimics the virus neutralization process. It uses horseradish peroxidase (HRP) conjugated 109 recombinant RBD protein and human angiotensin converting enzyme-2 (ACE-2) receptor protein. 110 The protein interaction between HRP-RBD and ACE-2 can be blocked by neutralizing antibodies 111 against SARS-CoV-2 RBD. Signal inhibition was calculated as follow: 112 Percent Signal Inhibition = (1-average optical density value of sample/average optical density value 113 of negative control) × 100% 114 The test results were interpreted as positive when the percent signal inhibition was ≥30%, which was 115 the cut-off for signal inhibition claimed by the manufacturer (6). For the test sample, if OD value was greater than the cut-off value and P/N ratio was more than 1.5, 124 sample was considered positive. While, for the test sample, if OD value was less than the cut-off 125 value and P/N ratio was less than 1.5, sample was considered negative (7). 126 Results of all four tests were given to participants with the understanding that testing was done in the 128 context of a research study. No clinical decisions were made on the basis of this study. Participants 129 were informed that a positive result did not preclude COVID-19 in the future and that a negative 130 result did not necessarily mean lack of protection against COVID-19. 131 Continuous variables like age were summarized with mean±SD, and categorical variables like gender 133 were presented with count (%). Primary analyses, to evaluate diagnostic accuracy of the 134 investigational kit, were reported with % for sensitivity and specificity. 95% confidence interval is 135 specified for sensitivity and specificity. Positive predictive value specifies the proportions of true 136 positive and negative predictive value species the proportions of true negative. In the vaccinated 137 groups, true positives are the samples that tested positive using the study kit and the comparator kit 138 and true negatives are the samples that tested negative using the study kit and the comparator kit. If 139 the sample test positive with the gold standard but negative with the investigational kit, it was 140 considered as false negative. If the sample test negative with the gold standard but positive with the 141 investigational kit, it was considered as false positive. For pre-pandemic control samples, all the 142 samples were considered as true negative as the samples were collected in 2018 before the emergence 143 of SARS-CoV-2 and therefore antibodies against SARS-CoV-2 could not be present in these 144 samples. So, in this group, any positives detected were considered as false positive and all negatives 145 reported were considered true negatives. Sensitivity and specificity were calculated using the 146 formulae: 147 Sensitivity: (True positive)/(True positive + False negative) 148 Specificity: (True negative)/(True negative + False positive) (6) 149 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 16, 2022. ; Demographic data of the subjects in the vaccinated group (n=62) are presented in Table 1. The 151 samples were collected at a median 62 (16-84) days after the second dose of vaccination in the 152 cohort of the total vaccinated population. The mean age of this population was 36.5±11.58 years; of 153 which 43.75% were male and 56.25% were female. Among this population, presence of co-154 morbidities such as hypertension, heart disease, and diabetes were 6.45%, 1.61%, and 4.84%, 155 respectively. Demographic details and co-morbidities for the COVISHIELD-and Covaxin-156 vaccinated groups are presented separately in Table 1 . 157 For further clarity, we performed individual analysis of all four kits for both the vaccinated groups 158 separately ( (Table 5) . 181 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. with GenScript cPass. The specificity was 100% against all three comparator tests. 220 A study in India comparing anti-Spike antibody responses following COVISHIELD and Covaxin 221 found that seropositivity and geometric mean titers were higher following COVISHIELD 222 vaccination compared to Covaxin vaccination (16). In our study, a significantly higher (p=0.01) level 223 of anti-RBD IgG antibodies were detected in the COVISHIELD-vaccinated group versus the 224 Covaxin-vaccinated group by the Abbott Quant kit. This may explain why Meril ABFind had a 225 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 16, 2022. ; https://doi.org/10.1101/2022.01.15.22269231 doi: medRxiv preprint better sensitivity in the COVISHIELD group compared to the Covaxin group. Additionally, Meril 226 ABFind does not detect antibodies against non-RBD epitopes. Covaxin is a whole virus inactivated 227 vaccine and generates antibody responses against Spike and non-Spike antigens, while Meril 228 ABFind only detects antibodies against the RBD. However, our study was not designed to compare 229 the seropositivity between COVISHIELD-and Covaxin-vaccinated individuals. Based on our study, 230 we cannot comment on the immunogenicity or efficacy of COVISHIELD compared with Covaxin. 231 The control samples were collected before the pandemic, and in this group the results of all four kits 232 differed. It was deemed impossible for these samples to contain antibodies against specific SARS-233 CoV-2 antigens as these samples were collected in 2018. Any positives in these samples would 234 necessarily be false positives due to cross reactivity with antibodies against other endemic 235 coronaviruses or other non-coronavirus pathogens. These samples were collected from patients with 236 an acute febrile illness which included dengue and leptospirosis but may have also included other 237 infectious diseases which may have resulted in cross reactivity and false positives. 238 In the pre-pandemic control samples, all positive results by Abbott Quant, MERILISA, and 239 GenScript cPass were classified as false positive results as it was not possible for these samples to 240 contain antibodies against SARS-CoV-2. The Meril ABFind kit did not produce a single false 241 positive in the pre-pandemic controls, and therefore in this cohort, Meril ABFind kit was 100% 242 specific, which was better than Abbott Quant IgG II, MERILISA, and GenScript cPass ( Figure 1 ). 243 Interestingly, Abbott Quant, MERILISA, and GenScript cPass detected 2.5%, 10%, and 12.5% false 244 positives, respectively. As all three of these kits (Abbott Quant, MERILISA, and GenScript cPass 245 kits) produced false-positive results in the pre-pandemic samples, it is possible that they produced 246 some false positives in the samples from the Covaxin-vaccinated subjects as well. It is possible that 247 Meril ABFind displayed a higher sensitivity in the Covaxin group while the comparator kits (Abbott 248 Quant, MERILISA, and GenScript cPass) displayed specificity lower than reported in literature. It 249 would be prudent to assess these assays in a large cohort of pre-pandemic samples from India to 250 ensure absence of cross-reactivity against non-SARS-CoV-2 coronaviruses or other pathogens. 251 Currently, many diagnostic kits which were developed to detect antibodies against SARS-CoV-2 in 252 specimens collected from infected and vaccinated individuals against COVID-19 are commercially 253 available. The rapid lateral flow serological assays were the first commercially available serological 254 assays, but their poor sensitivity and specificity made them unsuitable for use (11). Since then 255 numerous laboratory-based assays, for example CLIA & ELISA have been introduced in India with 256 reported high sensitivity and specificity. However, there is a lack of laboratory infrastructure, 257 technical expertise in rural India for such assays. Serological assays have demonstrated great value 258 in serological studies to understand the percentage of the population that has COVID-19 antibodies. 259 Such studies will continue to be relevant in the future. Serology has also been used to guide clinical 260 decision making. In the UK, NHS guidelines recommend offering a combination of casirivimab and 261 imdevimab to people aged 12 and over in hospital with COVID-19 who have no detectable SARS-262 CoV-2 antibodies (seronegative) (3). This treatment works best when administered early in disease 263 course and accurate point of care serological tests may offer value in this setting. While serology is 264 not currently used to guide decisions on vaccination, it is possible that in the future decisions on the 265 need for additional doses of COVID-19 vaccines or boosters will be based on serology. Therefore, 266 an accurate point of care serological test may offer value in future serological studies, clinical 267 decision making and vaccination programs. A rapid and accurate serological assay that can detect 268 post vaccination COVID-19 neutralizing antibodies would be especially useful in areas where 269 laboratory facilities are not available. 270 In this study, the Meril ABFind kit showed excellent sensitivity and specificity in the 271 COVISHIELD-and Covaxin-vaccinated groups. Notably, Meril ABFind kit was the only assay in 272 this study that had a zero false positivity rate and 100% specificity in the pre-pandemic samples, 273 while all three comparator kits had some false positives. This suggests the conventional thought 274 process that rapid point of care tests are necessarily less accurate or specific than laboratory based 275 assays may not always hold true, at least as concerns SARS-CoV-2 serological tests. 276 Our study also highlights the need to investigate laboratory based assays for cross reactivity in the 277 Indian population. If we had not used pre-pandemic samples as a control, we would have missed the 278 possibility that Abbott Quant, MERILISA, and GenScript cPass had a false positivity rate as high as 279 2.5%, 10% and 12.5%. While it is important to have sensitive assays that can correctly detect all 280 individuals who have an adaptive humoral response to SARS-CoV-2, it is equally important to 281 ensure that an assay is specific and doesn't incorrectly label those who do not have antibodies as 282 being sero-positive, particularly for neutralizing antibodies against SARS-COV-2. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. COVISHIELD-vaccinated group and 368 Covaxin-vaccinated group 369 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 16, 2022. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 16, 2022. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 16, 2022. ; https://doi.org/10.1101/2022.01.15.22269231 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 16, 2022. ; https://doi.org/10.1101/2022.01.15.22269231 doi: medRxiv preprint Figure 1 : Specificity of the four kits in the pre-pandemic control group 415 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 16, 2022. ; https://doi.org/10.1101/2022.01.15.22269231 doi: medRxiv preprint Author Correction: 316 Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor Neutralizing 319 antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival National Institute of Health and Care Excellence Developing antibody tests for SARS-CoV-2 Performance of the Abbott 326 SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 327 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global 328 Harmonization of COVID-19 Antibody Methods Performance evaluation of three 331 automated quantitative immunoassays and their correlation with a surrogate virus neutralization test 332 in coronavirus disease 19 patients and pre-pandemic controls A SARS-CoV-337 2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies Perspectives on the development of neutralizing antibodies against SARS-CoV-2 Neutralizing antibodies against SARS-CoV-2: 342 current understanding, challenge and perspective Performance 345 evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect 346 immunofluorescence and virus microneutralization test COVID-19-IgG-Quantitative-Antibody-Blood-Test Quantitative SARS-CoV-2 353 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection 354 status No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.